These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21297433)

  • 1. Palliative reirradiation for progressive diffuse intrinsic pontine glioma.
    Fontanilla HP; Pinnix CC; Ketonen LM; Woo SY; Vats TS; Rytting ME; Wolff JE; Mahajan A
    Am J Clin Oncol; 2012 Feb; 35(1):51-7. PubMed ID: 21297433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature.
    Freese C; Takiar V; Fouladi M; DeWire M; Breneman J; Pater L
    Pract Radiat Oncol; 2017; 7(2):86-92. PubMed ID: 28274399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group.
    Müller K; Scheithauer H; Pietschmann S; Hoffmann M; Rössler J; Graf N; Baumert BG; Christiansen H; Kortmann RD; Kramm CM; von Bueren AO
    Radiat Oncol; 2014 Aug; 9():177. PubMed ID: 25112658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience.
    Lassaletta A; Strother D; Laperriere N; Hukin J; Vanan MI; Goddard K; Lafay-Cousin L; Johnston DL; Zelcer S; Zapotocky M; Rajagopal R; Ramaswamy V; Hawkins C; Tabori U; Huang A; Bartels U; Bouffet E
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26988. PubMed ID: 29369515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reirradiation of recurrent breast cancer with and without concurrent chemotherapy.
    Würschmidt F; Dahle J; Petersen C; Wenzel C; Kretschmer M; Bastian C
    Radiat Oncol; 2008 Sep; 3():28. PubMed ID: 18801165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reirradiation for diffuse intrinsic pontine glioma: prognostic radiomic factors at progression.
    Wawrzuta D; Chojnacka M; Drogosiewicz M; Pędziwiatr K; Dembowska-Bagińska B
    Strahlenther Onkol; 2024 Sep; 200(9):797-804. PubMed ID: 38748214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton therapy for reirradiation of progressive or recurrent chordoma.
    McDonald MW; Linton OR; Shah MV
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1107-14. PubMed ID: 24267972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.
    Kline C; Liu SJ; Duriseti S; Banerjee A; Nicolaides T; Raber S; Gupta N; Haas-Kogan D; Braunstein S; Mueller S
    J Neurooncol; 2018 Dec; 140(3):629-638. PubMed ID: 30206764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
    McAvoy S; Ciura K; Wei C; Rineer J; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):819-27. PubMed ID: 25220718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 1/2 Trial of Reirradiation for Diffuse Intrinsic Pontine Glioma.
    Amsbaugh MJ; Mahajan A; Thall PF; McAleer MF; Paulino AC; Grosshans D; Khatua S; Ketonen L; Fontanilla H; McGovern SL
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):144-148. PubMed ID: 30610915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemo-reirradiation in persistent/recurrent head and neck cancers.
    Nagar YS; Singh S; Datta NR
    Jpn J Clin Oncol; 2004 Feb; 34(2):61-8. PubMed ID: 15067097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.
    Sulman EP; Schwartz DL; Le TT; Ang KK; Morrison WH; Rosenthal DI; Ahamad A; Kies M; Glisson B; Weber R; Garden AS
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):399-409. PubMed ID: 18556144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients.
    De Crevoisier R; Bourhis J; Domenge C; Wibault P; Koscielny S; Lusinchi A; Mamelle G; Janot F; Julieron M; Leridant AM; Marandas P; Armand JP; Schwaab G; Luboinski B; Eschwege F
    J Clin Oncol; 1998 Nov; 16(11):3556-62. PubMed ID: 9817275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?
    Teo PM; Kwan WH; Chan AT; Lee WY; King WW; Mok CO
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):897-913. PubMed ID: 9531376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
    Rusthoven KE; Feigenberg SJ; Raben D; Kane M; Song JI; Nicolaou N; Mehra R; Burtness B; Ridge J; Swing R; Lango M; Cohen R; Jimeno A; Chen C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1020-5. PubMed ID: 20231078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.
    Bouffet E; Raquin M; Doz F; Gentet JC; Rodary C; Demeocq F; Chastagner P; Lutz P; Hartmann O; Kalifa C
    Cancer; 2000 Feb; 88(3):685-92. PubMed ID: 10649264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.
    Sethi R; Allen J; Donahue B; Karajannis M; Gardner S; Wisoff J; Kunnakkat S; Mathew J; Zagzag D; Newman K; Narayana A
    J Neurooncol; 2011 Mar; 102(1):121-7. PubMed ID: 20623246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort.
    Scholtyssek F; Zwiener I; Schlamann A; Seidel C; Meixensberger J; Bauer M; Hoffmann KT; Combs SE; von Bueren AO; Kortmann RD; Müller K
    Radiat Oncol; 2013 Jul; 8():161. PubMed ID: 23822643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
    Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.